Baxter’s third quarter results were met with a negative market reaction, as the company delivered top-line growth but missed Wall Street’s revenue expectations. Management attributed performance ...

According to SNS Insider's forecast, the global Antisense and RNAi Therapeutics market will grow from USD 4.15 billion in 2023 to USD 18.48 billion by 2032, at a compound annual growth rate (CAGR) of ...

CLN-049 achieved promising anti-leukemic activity in this heavily pretreated AML population: Anti-leukemic activity was observed at target doses =6 µg/kg (n=23, all AML), with a CRc rate of 30%, and ...